-
-
-
-
-
-
-
Zentalis Pharmaceuticals (ZNTL) PT Raised to $10 at Guggenheim
-
-
-
-
-
-
-
Zentalis advances azenosertib toward potential ovarian cancer approval in 2026
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)
-
-
-
-
-
-
-
Zentalis Pharmaceuticals (ZNTL) Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
-
-
-
-
-
-
-
UBS Downgrades Zentalis Pharmaceuticals (ZNTL) to Neutral
-
-
-
-
-
-
-
Zentalis Pharmaceuticals (ZNTL) Provides Update on Azenosertib Clinical Development Program
443,899 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

